Floatz logo

Trastuzumab Imbotolimod

HER2-positive Gastroesophageal Cancer

Bolt Biotherapeutics, Inc.antibody_drug_conjugatePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

47 Active assets in the HER2-positive Gastroesophageal Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
Iambic Therapeutics, Inc
Phase 1/2B
Eloxatin
Incyte Corporation
Phase 1/2B
FLUOROURACILUM
Incyte Corporation
Phase 1/2B
Cyclophosphamide
Diwakar Davar
Phase 2B
Pembrolizumab
Diwakar Davar
Phase 2B

View all 50 →

Same molecule, other indications

Trastuzumab Imbotolimod is also rated in:

HER2 positive breast carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
51 / 100
View asset →
endometrial carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →